BioNTech, Pfizer stocks rally after first participants in U.S. trial of COVID-19 vaccine were dosed

Shares of BioNTech SE BNTX, 3.22% rallied 4.8% in premarket trading, after the immunotherapy company and Pfizer Inc. PFE, 0.35% said Tuesday that the first participants in the phase 1/2 trial for the BNT162 vaccine program to prevent COVID-19 have been dosed in the U.S. Pfizer's stock rose 1.3% ahead of the open. The companies said stage 1 of the trial in the U.S. will enroll up to 360 healthy people in the 18-55 and 65-85 age cohorts. Pfizer and BioNTech said the development program includes four vaccine candidates. "We are optimistic that advancing multiple vaccine candidates into human trials will allow us to identify the safest, most effective vaccination options against COVID-19," said BioNTech Chief Executive Ugur Sahin. Shares of BioNTech have soared 56.5% over the past three months through Monday and Pfizer's stock has slipped 1.4%, while the Dow Jones Industrial Average DJIA, -0.35% has lost 18.9%.